Metoprolol bradycardia
Pro Research Analysisby 
Searched over 200M research papers for "metoprolol bradycardia"
Metoprolol-Induced Bradycardia: Incidence and Risk Factors
Bradycardia, or a slow heart rate, is a recognized side effect of metoprolol, a commonly used beta-blocker. The risk and severity of bradycardia with metoprolol can be influenced by several factors, including genetics, sex, drug interactions, and underlying health conditions.
CYP2D6 Polymorphism and Metoprolol Bradycardia
Metoprolol is primarily metabolized by the liver enzyme CYP2D6. Individuals with poor CYP2D6 metabolism (due to genetic polymorphisms or drug interactions) have higher metoprolol concentrations, which increases the risk of bradycardia. Studies show that poor metabolizers experience a greater reduction in heart rate and are at a higher risk for bradycardia compared to those with normal metabolism, with some reports indicating up to a fourfold increase in bradycardia risk for poor metabolizers 1568. Genetic testing for CYP2D6 variants may be helpful in patients who experience strong side effects or are on multiple medications 168.
Drug Interactions Increasing Bradycardia Risk
Certain medications can inhibit CYP2D6, leading to higher metoprolol levels and increased bradycardia risk. For example, terbinafine, a common antifungal, can significantly reduce metoprolol clearance, resulting in severe bradycardia . However, large population studies found that antidepressants known to inhibit CYP2D6 (such as fluoxetine and paroxetine) did not significantly increase the risk of bradycardia when used with metoprolol compared to other antidepressants .
Sex Differences in Metoprolol-Related Bradycardia
Women tend to have higher plasma concentrations of metoprolol than men when given the same dose. Research indicates that women, but not men, have a significantly increased risk of bradycardia at higher metoprolol concentrations, even after adjusting for other health factors .
Comparison with Other Beta-Blockers and Rate-Control Agents
When compared to carvedilol, metoprolol is associated with a higher risk of emergent bradycardia, although the overall incidence remains low in clinical practice . In patients with heart failure and atrial fibrillation, metoprolol is more likely to cause bradycardia and dose reductions than bucindolol, and fewer patients on metoprolol reach the target dose due to bradycardia .
Metoprolol vs. Diltiazem: Bradycardia Risk in Atrial Fibrillation
Meta-analyses comparing metoprolol and diltiazem for atrial fibrillation with rapid ventricular rate found no significant difference in the rates of bradycardia between the two drugs. Both agents are associated with low rates of bradycardia, and the risk is more closely related to the patient’s initial heart rate than the choice of medication 910.
Conclusion
Metoprolol can cause bradycardia, especially in individuals with poor CYP2D6 metabolism, women, and those taking certain interacting drugs. While the overall risk is low, careful monitoring and consideration of genetic and drug interaction factors can help minimize adverse effects. In clinical practice, individualized dosing and awareness of patient-specific risk factors are important for safe metoprolol use.
Sources and full results
Most relevant research papers on this topic